Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.

Catalano, Martina; Francesco Iannone, Luigi; Cosso, Federica; Generali, Daniele; Mini, Enrico; Roviello, Giandomenico

Catalano, Martina; Francesco Iannone, Luigi; Cosso, Federica; Generali, Daniele; Mini, Enrico; Roviello, Giandomenico.

Afiliação

Catalano M; School of Human Health Sciences, University of Florence, Florence, Italy.
Francesco Iannone L; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
Cosso F; School of Human Health Sciences, University of Florence, Florence, Italy.
Generali D; Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Mini E; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Expert Opin Ther Targets ; 26(11): 923-936, 2022 11.

Article em En | MEDLINE | ID: mdl-36519314

Assuntos

Neoplasias; Inibidores de Poli(ADP-Ribose) Polimerases; Humanos; Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia; Dano ao DNA; Neoplasias/tratamento farmacológico; Neoplasias/genética; Microambiente Tumoral

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Poli(ADP-Ribose) Polimerases / Neoplasias Limite: Humans Idioma: En Revista: Expert Opin Ther Targets Assunto da revista: TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google